Employees: 99
Size CapsoVision (CV) is a United States Health Care company (Medical Specialties) with a market value of $366M, the 2916th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.82 on 18 Nov 2026.
Performance Over six months the shares gained 5.2%, against -14.4% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 15.3% over the last twelve months (peer median +10.5%); the operating margin is -212.6% (peer median 12.2%).
Valuation It trades at 24.8× enterprise value to sales against a peer median of 1.8× (3rd most expensive of 21).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | $13.9M | $13.6M | $11.8M | $9.75M |
| Revenue growth | — | +15% | +21% | — |
| Gross profit | $6.92M | $7.17M | $6.38M | $5.49M |
| EBITDA | -$29.0M | -$24.8M | -$19.5M | -$10.8M |
| Net income | -$29.2M | -$25.3M | -$19.9M | -$11.3M |
| Free cash flow | -$29.3M | -$23.0M | -$20.2M | -$11.6M |
| Capital expenditure | $78,000 | $90,000 | $153,000 | $754,180 |
| Total debt | $780,000 | $887,000 | $1.24M | $1.51M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CV | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.1% | -12.7% | 2nd highest of 21 |
| 6-month return | +5.2% | -14.4% | 6th highest of 20 |
| Distance from 52-week high | -55.6% | -42.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +15.3% | +10.5% | 9th highest of 21 |
| Operating margin | -212.6% | 12.2% | 2nd lowest of 21 |
| EV / Sales | 24.8× | 1.8× | 3rd most expensive of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 1.8× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | 3.7× | -13.1% | +36.8% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 4.2× | 5.7% | +3.4% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 5.4× | 18.4% | +4.4% |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 7.8× | n/a | n/a |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 1.4× | -10.3% | +16.9% |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | 1.8× | -9.5% | -6.6% |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| YD Bio YDES | United States | $344M | +7% | +17% | -883% | 571.2× | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | 1.7× | n/a | n/a |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | 1.8× | n/a | n/a |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 5.5× | -6.3% | +247.0% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 1.0× | -17.6% | +15.4% |
| COLTENE CLTN.SW | Switzerland | $339M | -7% | -2% | 8% | 1.4× | -0.3% | -0.7% |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | 4.6× | 41.7% | +15.9% |